Aakha Biologics Presents White Paper on Novel Treatment for Non-Small Cell Lung Cancers
Aakha Biologics is working on a new way to treat non-small cell lung cancers (NSCLC) with concurrent KRAS LKB1 mutations, which generally do not respond well to current immune checkpoint blockade therapies. They are focusing on a special protein called MICA/B, which helps the body's natural killer (NK) cells attack this cancer. Their innovative antibody, AHA-1031, makes it easier for the immune system to fight cancer by keeping MICA/B on the cancer cells and stabilizing the protein expression.
Aakha Biologics Presents White Paper on Novel Treatment for Non-Small Cell Lung Cancers
